Takeda taps BridGene to pursue hard-to-drug neurodegenerative disease targets

Takeda has teamed up with BridGene Biosciences to discover small molecules against targets once thought to be undruggable. The five-program agreement, which is potentially worth more than $500 million, wraps up a busy month for deal-making at Takeda.